Syncell, a leader in advanced subcellular protein purification and spatial proteomics analysis, has successfully closed a $15 million Series A funding round, bringing its total funding to $30 million. The capital will be used to drive the global commercialization and support of the company’s innovative Microscoop platform. The funding round was led by Taiwania Capital, with participation from both new and existing investors.
Syncell, a leader in subcellular protein purification and spatial proteomics, announced the successful closing of a $15 million Series A funding round, bringing its total funding to $30 million. This investment will support the global commercialization of Syncell’s Microscoop platform, a cutting-edge tool for spatial proteomics. The funding round was led by Taiwania Capital, with participation from both new and existing investors.
“We are proud of Syncell’s progress in 2024, with the upcoming placement of instruments across the U.S., Europe, and Asia, along with new office openings in the U.S. and Taiwan,” said Jung-Chi Liao, Ph.D., founder and CEO of Syncell. “The Series A funding will fuel our next growth phase, enabling us to expand our commercial team and scale operations to meet the increasing demand for our technology from spatial and cell biologists. This will help them accurately discover new protein components from targeted regions of interest.”
Jerome Shen, General Partner of Taiwania’s Bio Fund, added, “Syncell has immense potential to transform spatial biology and proteomics research. The company’s ability to deliver high sensitivity and specificity in protein detection, combined with AI-driven photolabeling for targeted analysis, offers exciting opportunities to build new models of biology.”
The Microscoop platform enables high-precision, unbiased spatial proteomic discovery within subcellular tissues or cells. It can accurately identify new protein components from specific regions, enabling spatial protein purification. This aids researchers in identifying novel protein drug targets at disease-associated sites, biomarkers, and mechanisms of biological pathways. The technology supports research in oncology, neurodegenerative diseases, infectious diseases, metabolic diseases, developmental biology, and drug discovery applications. Recently, the Microscoop platform won the “Proteomics Solution of the Year” award at the Biotech Breakthrough Awards 2024.
Wilfried Rossoll, Ph.D., Associate Professor of Neuroscience at the Mayo Clinic, commented, “Syncell’s spatial opto-proteomics platform enables the discovery of proteins in disease-associated aggregates in human brain tissue. This unbiased approach uncovers potential biomarkers and therapeutic targets, which other spatial biology methods cannot achieve.”
Syncell is also building relationships with technology partners, recently signing a memorandum of understanding with Thermo Fisher Scientific to integrate its mass spectrometer instruments with the Microscoop platform. These partnerships will support the company’s growth across various industry segments.
Syncell is set to launch its Microscoop Mint product line and demonstrate its capabilities at Cell Bio 2024, the joint meeting of the American Society for Cell Biology (ASCB) and the European Molecular Biology Organization (EMBO), taking place from December 14-18 in San Diego. Attendees can visit booth #639 and attend the tech talk, “Reinventing the Proteome: Microscopy-Guided Subcellular Protein Isolation with the Syncell Microscoop” on December 16 at 3:15 p.m. PT.
About Syncell: Syncell, founded in 2020, is a commercial-stage life sciences company specializing in subcellular protein purification and spatial proteomics. The company’s Microscoop® technology, developed by founder Dr. Jung-Chi Liao at Academia Sinica in Taiwan, allows researchers to achieve unbiased discoveries in spatial proteomics at disease sites. Headquartered in Taipei, Taiwan, and Watertown, Mass., Syncell has raised $30 million to date.
